Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) fell 7.1% during mid-day trading on Wednesday . The stock traded as low as $0.39 and last traded at $0.39. 1,160,771 shares traded hands during mid-day trading, an increase of 426% from the average session volume of 220,624 shares. The stock had previously closed at $0.42.
The firm has a market capitalization of $18.61 million, a PE ratio of -0.38 and a beta of 2.38.
An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Virtu Financial LLC raised its holdings in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 465.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,391 shares of the specialty pharmaceutical company’s stock after acquiring an additional 56,299 shares during the quarter. Virtu Financial LLC owned approximately 0.16% of Eyegate Pharmaceuticals worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 40.81% of the company’s stock.
WARNING: This story was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://dakotafinancialnews.com/2019/03/21/eyegate-pharmaceuticals-eyeg-stock-price-down-7-1.html.
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Featured Story: Why is the ex-dividend date different from the record date?
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.